Niox Group Regulatory News (NIOX)

NIOX Group plc

("NIOX" or the "Company" and, together with its subsidiaries, the "Group")

AGM Statement

Oxford, UK - 21 May 2026: NIOX Group plc (AIM: NIOX), a medical device company focused on point-of-care FeNO testing for the diagnosis, monitoring and management of asthma and COPD, is holding its Annual General Meeting at 11.00 am today at the Magdalen Centre, 1 Robert Robinson Ave, The Oxford Science Park, Oxford, OX4 4GA.

Trading Update

We are pleased to report that trading for the year to date has been in line with management expectations, with cash of £22.3 million as at 30 April 2026 following payment of prior-year bonuses (31 December 2025: £19.9 million). A trading update for the six months ending 30 June 2026 will be released in mid-July.

NIOX has signed a ten-year exclusive supply agreement with its FeNO sensor supplier. This allows NIOX to make targeted investments in the sensor supplier to increase manufacturing capacity, strengthen long-term supply security and enhance operational resilience as the business continues to scale globally. 

NIOX remains focused on its core strategic priorities for 2026, which are:

· Increasing the penetration of FeNO testing and the use of NIOX® in the US.

· Rolling out the NIOX PRO® device, with regulatory approvals expected across various markets throughout 2026.

· Continuing the development of the NIOX MyNO® home-use device.

-Ends-